## The Prajs-Drimmer Institute for Development of Anti-Degenerative Drugs, Tel Aviv University

April 2021

Dear researchers,

The Prajs-Drimmer Institute for development of Anti-Degenerative Drugs at Tel Aviv University was established by the Prajs-Drimmer family to enhance innovative studies towards the development of anti-degenerative drugs.

The Prajs-Drimmer Institute opened a new program for funding part of the scholarship of excellent PhD students. The Institute will fund a number (7-9) of scholarships this year (25%). The scholarships will be devoted for translational research in the field of neurodegenerative diseases.

Please note the following criteria:

- 1. Research field of the student should be neurodegeneration or development of antidegenerative drugs.
- 2. Candidate should be in his/her second year or third year of the PhD (after the proposal).
- 3. Applicants should submit a 2-page proposal describing their PhD goals and preliminary results (English, font: Arial 11/Times New Roman 12, line spacing: 1.5) including:
- Student name (name and affiliation)
- Project title
- Scientific background
- Specific aims
- Experimental design (outline)
- Uniqueness and significance and relationship to anti-neurodegenerative drugs development (not exceeding 300 words)
- Up to 10 references (can beyond the 2 pages)
- In the same pdf file, the applicants should provide: A short CV and list of publications.
- A letter of recommendation should be submitted separately.
- \* Eligibility: The submitting student must be a Tel Aviv University student, who is **not** funded by other programs.
- Deadline for proposal submission: 3/05/2021
- Winner announcement until the Institute ceremony 18/5/2021(may be requested to give a brief lecture)
- \* Funding of selected projects will begin: 1/10/2021
- \* Proposals and letters should be submitted electronically to:

Tal Oded: taloded@tauex.tau.ac.il

\* Proposals not written in accordance with the requested format will not be considered. Upon submission, an electronic confirmation of receipt will be sent by Tal Oded.

Sincerely,

Prof. Pinkas-Kramarski Ronit

Head, Prajs-Drimmer Institute for Development of Anti-Degenerative Drugs,

Faculty of Life Sciences

Tel Aviv University

Pinkas Ronit

